Physics-First Drug Design: Expanding Beyond AI’s Reach
Discovering new drugs means searching a chemical universe so vast that most possible molecules have never been synthesized or measured. Verseon takes a physics-first route that starts from protein structure and atomic principles, aiming to produce molecular scaffolds that lie outside the maps learned by data-driven AI models.
The Limitations of AI in Novel Drug Creation
Modern AI platforms are powerful at interpolation: predicting properties and optimizing variants within the distribution of known compounds. But when asked to extrapolate and propose fundamentally new chemistry, data-hungry models can struggle because they rely on patterns in existing datasets. As Verseon CEO Adityo Prakash frames it, AI is excellent at filling in gaps among known points, not at pointing to entirely new regions of chemical space.
Verseon’s Deep Quantum Modeling Approach
Verseon begins with the target protein and builds candidate molecules atom by atom using molecular and quantum physics calculations. These first-principles designs are prioritized by predicted binding and synthetic plausibility, then validated experimentally. Only after physics-driven hits are confirmed does Verseon apply AI to generate optimized variants and accelerate lead development. This sequence flips the common order used by many AI-first startups.
Promising Candidates for Unmet Medical Needs
Physics-first design has produced candidates that aim to address unmet clinical needs. Verseon is developing precision oral anticoagulants intended to retain potency while dramatically reducing bleeding risk. The company also reports oral small molecules for diabetic eye disease that would avoid invasive ocular injections. These examples illustrate how novel chemistries can unlock therapeutic profiles not achievable with incremental modifications to known drugs.
Charting a New Course for Drug Discovery
By privileging physics-based discovery before applying AI for refinement, Verseon seeks to expand the boundaries of drug space rather than staying inside it. For investors, researchers, and policymakers, this approach highlights a complementary route to AI that may be essential for finding medicines that could not be predicted from existing data alone.
